Journal of Cancer Prevention最新文献

{"title":"A Qualitative Study of Staff and Provider Experiences with Follow-up Colonoscopy in a Community Health Center and Gastroenterology Specialty.","authors":"Cynthia M Mojica, Jennifer L Schneider, Jamie H Thompson, Gloria D Coronado","doi":"10.15430/JCP.25.025","DOIUrl":"10.15430/JCP.25.025","url":null,"abstract":"<p><p>Colorectal cancer screening is an effective strategy to prevent disease, reduce the risk of advanced-stage diagnosis, and improve survival. Timely follow-up of abnormal screening results, particularly abnormal fecal immunochemical tests, is essential to realizing these benefits. This qualitative study examined routine processes related to colonoscopy referral and completion for patients of a federally qualified health center (FQHC) referred to community gastroenterology (GI) practices. Using a snowball sampling approach, five FQHC individuals and eight community GI practice individuals were interviewed. Interviews at the FQHC were conducted between March 2020 and September 2021, during the early phase of the coronavirus disease 2019 pandemic. Due to clinic closures and other pandemic-related disruptions, GI practice interviews occurred between August 2021 and January 2023. Study findings highlight the need for improved communication and collaboration between primary care and GI practices to support colonoscopy completion among low resource populations. Interviewees also offered recommendations to ensure colonoscopy completion. Further research is needed to pilot test centralized referral and scheduling systems and to develop multicomponent interventions that address both patient and organizational barriers to colonoscopy completion.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 4","pages":"185-195"},"PeriodicalIF":1.8,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12715431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Disparity in Cancer and Non-cancer Mortality among Korean Cancer Survivors.","authors":"Ansun Jeong, Soyeoun Kim, Somin Jeon, Boyoung Park","doi":"10.15430/JCP.25.033","DOIUrl":"10.15430/JCP.25.033","url":null,"abstract":"<p><p>This study assessed sex disparities in the causes of death (CODs), both related to cancer and non-cancer, in a nationwide database of cancer survivors in South Korea. Our database included cancer cases diagnosed in Korea between 2009 and 2016, and their CODs up to 2021. Deaths were classified into three categories: index-cancer, non-index-cancer, and non-cancer causes. Male-to-female age-standardized mortality ratios (M/F SMRs) were computed by dividing the male-specific mortality rate by the corresponding female-specific rate. Out of a total of 279,104 (49.0%) recorded deaths in male survivors and 141,674 (27.9%) deaths in female survivors, the M/F SMRs showed an elevated mortality risk in males, both for cancer-related causes (1.46, 95% CI 1.45-1.47) and non-cancer CODs (1.75, 95% CI 1.74-1.77). Among non-cancer CODs, the most significant sex disparity in mortality risk was evident in deaths attributed to chronic lower respiratory diseases (CLRDs), with an SMR of 4.51 (95% CI 4.30-4.73), followed by mortalities due to intentional self-harm (suicide) (2.95, 95% CI 2.85-3.05) and transportation accidents (SMR 2.86, 95% CI 2.67-3.04). Subgroup analysis focusing on survivors of common cancer sites indicated a relatively consistent pattern in index cancer deaths, but the M/F SMRs for non-index cancer and non-cancer deaths demonstrated variability across different cancer sites. Our study underscores an overall elevated mortality risk in male cancer survivors compared to female counterparts. Although deaths stemming from primary cancer remain a substantial concern for both sexes, disparities in non-cancer deaths warrant considerable attention, particularly in relation to CLRD and intentional self-harm (suicide) among male survivors.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 4","pages":"196-204"},"PeriodicalIF":1.8,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12715430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Oncological Clinical Trials in African Countries: A Scoping Review.","authors":"Kumban Walter Chuck, Tung Hoang, Jeongseon Kim","doi":"10.15430/JCP.25.021","DOIUrl":"10.15430/JCP.25.021","url":null,"abstract":"<p><p>Africa has increasingly participated in clinical trials; however, there is limited literature on the trends of oncological clinical trial registration. This study aims to review the patterns of oncological clinical trials conducted in Africa between 2000 and 2024. Three major trial registries-Pan African Clinical Trial Registry (PACTR), ClinicalTrials.gov (CTG), and the International Standard Randomized Controlled Trial Number (ISRCTN)-were utilized. Data were extracted and analyzed descriptively using Microsoft Excel (Microsoft Corporation). CTG recorded the highest number of registered trials (n = 458), followed by PACTR (n = 148) and ISRCTN (n = 69). Egypt, Algeria, and South Africa contributed the most to these registrations. The number of trials gradually increased after 2010, peaking between 2018 and 2019. Randomized study designs were the most common, representing at least 80% of trials in the CTG and PACTR registries. Breast and cervical cancers were the most frequently studied cancer types, although few trials had published results. The completeness of trial information varied by registry: CTG (47.8%), PACTR (33.1%), and ISRCTN (84.1%). Only the ISRCTN registry consistently reported data on registration timing, whereas phases II and III were the most commonly represented trial phases in the CTG and ISRCTN registries. In conclusion, although there has been a gradual increase in oncological clinical trial activity in Africa, published outcomes remain limited. This study highlights the need to improve trial registration practices and promote the timely publication of results across the continent.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 3","pages":"154-165"},"PeriodicalIF":1.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary and Secondary Prophylaxis for Diseases Caused by Human Papillomavirus Infections.","authors":"Meri Arman Hristamyan","doi":"10.15430/JCP.25.018","DOIUrl":"10.15430/JCP.25.018","url":null,"abstract":"<p><p>Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and a leading cause of several cancers, including cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, as well as benign conditions such as genital warts. The global burden of HPV is particularly high in low- and middle-income countries due to disparities in vaccine accessibility, screening, and awareness. This review synthesizes recent advances in the primary and secondary prophylaxis of HPV-related diseases. Primary prophylaxis encompasses vaccination, education, and behavioral interventions. Although effective vaccines and gender-neutral vaccination policies exist, global uptake remains suboptimal, especially among males and in resource-limited settings. Different educational and school-based vaccination programs have demonstrated success in increasing coverage, while behavioral measures such as safe sexual practices, condom use, and male circumcision have been shown to reduce transmission risk. Secondary prophylaxis focuses on early detection and treatment of precancerous lesions, with HPV-DNA testing now the preferred method for cervical cancer screening, while standardized screening protocols for men are lacking. Treatment ranges from topical agents to excisional procedures and ablative therapies for cervical intraepithelial neoplasia and other precancerous lesions, depending on the type and severity. However, access to timely and effective treatment remains suboptimal in many regions. Addressing gaps in the primary and secondary prevention is essential for reducing the global impact of HPV and achieving international cancer prevention goals.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 3","pages":"146-153"},"PeriodicalIF":1.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Mesenchymal Stem Cells in Drug Resistance in Lung Neoplasms.","authors":"Dongho Kang, Eunhee Yeon, Sunyoung Kim, Eunjin Han, Taejo Kang, Hyekyung Song, Jiyoung Kim","doi":"10.15430/JCP.25.015","DOIUrl":"10.15430/JCP.25.015","url":null,"abstract":"<p><p>The tumor microenvironment (TME) is a decisive determinant of therapeutic response and the emergence of drug resistance in lung cancer. Among its stromal constituents, mesenchymal stem cells (MSCs) are pivotal regulators of disease progression because they secrete diverse paracrine mediators. Accumulating evidence indicates that MSC-derived cytokines, growth factors, and extracellular vesicles (EVs) drive epithelial-mesenchymal transition (EMT)-a phenotypic shift that augments cellular motility, invasiveness, and stem-like traits. EMT contributes directly to resistance against epidermal growth factor receptor tyrosine kinase inhibitors and platinum-based chemotherapy. Key MSC-secreted factors, such as TGF-β1, interleukin-6, and C-C motif chemokine ligand 5, activate signal transducer and activator of transcription 3, phosphoinositide 3-kinase/AKT, and Wnt/β-catenin cascades, thereby reinforcing drug-resistant phenotypes. MSC-induced EMT also remodels immune surveillance and supports the persistence of residual tumor clones. Elucidating the molecular reciprocity between MSCs and lung cancer cells within the TME is indispensable for rational therapy design. This review synthesizes current mechanistic insights into MSC-mediated EMT-driven resistance and discusses translational strategies including targeted inhibition of paracrine signaling and EV engineering that may restore drug sensitivity in lung cancer.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 3","pages":"138-145"},"PeriodicalIF":1.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Aspirin on Development of First and Recurrent Primary Cutaneous Keratinocyte Carcinomas in Older Australian Adults: Extended Follow-up of a Large Randomised Controlled Trial.","authors":"Emma Hiscutt, Mabel Yan, Victoria Mar, Rory Wolfe, Ruth Trevaks, Michelle Wilson, Suzanne Gaye Orchard","doi":"10.15430/JCP.25.017","DOIUrl":"10.15430/JCP.25.017","url":null,"abstract":"<p><p>Keratinocyte carcinomas (KC) are the most frequent cancers diagnosed in Australia and impart the largest economic cost of all cancers. Predisposed individuals tend to develop multiple KC over their lifetime. Data from the ASPirin in Reducing Events in the Elderly (ASPREE) randomized controlled trial with post-trial observational follow up (ASPREE-eXTension) were analysed, to compare the KC incidence among older Australians randomized to daily 100 mg aspirin or placebo, and to determine whether aspirin influenced multiple primary KC development. Participants were linked to the Medicare Benefits Schedule for KC ascertainment; medical history was collected at ASPREE enrolment. A Cox proportional hazards model was used to estimate hazard ratios (HR) for KC incidence, and was adjusted for age, sex and race. The Anderson and Gill recurrent event model compared the incidence of multiple KC between aspirin and placebo groups. Thirteen thousand eight hundred thirty-eight participants (6,850 aspirin treated, 6,988 placebo) were analysed over median 6.8 years (trial period 4.7 years); 36.1% developed a KC and 20.7% developed multiple primary KCs. Randomization to aspirin was not significantly associated with KC incidence, (adjHR = 0.97, 95% CI [0.92 to 1.03], <i>P</i> = 0.31). However, it did decrease the rate of multiple KC development (adjHR = 0.93, 95% CI [0.88 to 0.99], <i>P</i> = 0.02). This post-hoc analysis of a large trial with post-trial observational follow-up showed that aspirin did not influence the incidence, but decreased the rate of multiple KC.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 3","pages":"177-184"},"PeriodicalIF":1.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Primary Colon and Duodenal Tumor Cultures from the Apc-mutant Pirc Rat for Screening Preventive Agents.","authors":"Ahmed Muhsin, Sultan Neja, Nivedhitha Mohan, Sabeeta Kapoor, Jorge Enrique Tovar Perez, Wan-Mohaiza Dashwood, Asif Rashid, Roderick Dashwood, Praveen Rajendran","doi":"10.15430/JCP.25.016","DOIUrl":"10.15430/JCP.25.016","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with genetic, epigenetic, and immune-dependent mechanisms contributing to disease pathogenesis. Preventive strategies are especially important for individuals with hereditary syndromes such as familial adenomatous polyposis (FAP), in which <i>Adenomatous Polyposis Coli</i> (<i>APC</i>) mutations drive early tumor formation. The polyposis in rat colon (Pirc) model, harboring an <i>Apc</i> mutation, faithfully recapitulates the development of adenomatous polyps, a precursor stage of CRC, in both the colon and duodenum. Here, we report the generation and characterization of primary cell cultures derived from 30 colonic and duodenal adenomas (benign tumors) from Pirc rats. These Pirc colon adenoma and duodenal adenoma cultures demonstrated consistent morphology, epithelial marker expression (E-cadherin and pan-cytokeratin), and robust 3D spheroid formation. Growth kinetics revealed a doubling time of 50 ± 4 hours. Notably, histone deacetylase and bromodomain inhibitors reduced cell viability and colony formation significantly, highlighting the synergistic potential in targeting deregulated epigenetic signatures as early-stage prevention strategies in FAP. These primary cultures, maintained between passages 5 and 10 to preserve phenotypic integrity, offer a valuable ex vivo model for early-stage CRC research and the screening of preventive agents. By bridging genetic susceptibility and translational prevention, this platform provides a novel and reproducible tool for advancing cancer interception.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 3","pages":"166-176"},"PeriodicalIF":1.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Aging-related Metabolic and Biological Markers between Cancer Survivors and Healthy Populations: A Systematic Review.","authors":"Nur Afifah Mursyida Zaujan, Mohd Razif Shahril, Suzana Shahar, Ezanee Azlina Mohamad Hanif, Nur Fa'izah Ab Muin, Razinah Sharif, Ponnusamy Subramaniam, Michael Fenech","doi":"10.15430/JCP.25.012","DOIUrl":"10.15430/JCP.25.012","url":null,"abstract":"<p><p>Cancer survivors may exhibit biological and metabolic changes linked to both cancer and its treatment. This systematic review aimed to compare metabolic and biological aging-related biomarkers between cancer survivors and healthy individuals. The primary electronic databases utilized to search papers from 2019 to 2024 were PubMed, Scopus, and Web of Science. Boolean operators were combined with specific keywords and MESH terms in searching the articles. After excluding protocol papers, studies with incorrect designs or populations, and animal studies, 27 articles were selected for data extraction, synthesis, and quality evaluation. The articles were checked for quality by using the National Institutes of Health (NIH) checklist for observational cohort and cross-sectional studies. Cancer survivors had significant differences in aging-related metabolic and biological biomarkers compared to a healthy population. These include aberrant DNA methylation (hypermethylation, hypomethylation, and epigenetic modification), abnormal expression levels of lipid profiles (high-density lipoprotein, low-density lipoprotein level, malondialdehyde, and apolipoprotein C-1), inflammatory markers (interleukins, C-reactive protein, and TNF-α), immune-senescence (Cellular Communication Network Factor 3 protein), energy regulation (leptin, adiponectin, and mitochondria function profiles), and poor oral and bone health. These findings reflect the accelerated biological age and increased vulnerability to age-related diseases among cancer survivors, as compared to healthy populations. However, considering the cross-sectional design limitations, causal relationships between cancer diagnosis and alterations in biological aging cannot be confirmed. To establish whether cancer itself contributes to accelerated aging, future longitudinal studies are needed that assess metabolic and biological biomarkers in individuals from the time of diagnosis onward.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 3","pages":"121-137"},"PeriodicalIF":2.5,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esculetin Attenuates the Migration and Invasion of Human Hepatocellular Carcinoma Cells by Attenuating Matrix Metalloproteinase Activity and Strengthening Tight Junctions.","authors":"Sung Ok Kim, Hyun Hwangbo, Su Hyun Hong, Yung Hyun Choi","doi":"10.15430/JCP.25.014","DOIUrl":"10.15430/JCP.25.014","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a highly malignant liver cancer that metastasizes to various organs. Esculetin, a natural dihydroxy coumarin derivative, has been shown to have a variety of pharmacological properties, including immune-enhancing, antioxidant, and anti-inflammatory effects. Esculetin is also known to have potent anticancer activity; however, studies on its ability to inhibit cancer cell metastasis are relatively rare. In this study, we investigated how esculetin inhibits the migration and invasion of human hepatocellular carcinoma cell lines Hep3B and HepG2, and elucidated the underlying mechanisms. Our results showed that esculetin markedly suppressed the migration and invasion of HCC cells, and this was associated with a decrease in the expression and activity of matrix metalloproteinase (MMP)-9 and MMP-2, and increased expression levels of tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2. In addition, esculetin enhanced the tightening of tight junctions by suppressing the expression of claudin family proteins.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 2","pages":"111-117"},"PeriodicalIF":2.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoprevention of Keratinocyte Cancers: Could Aspirin Be the Solution?","authors":"Emma Hiscutt, Suzanne Orchard, Rory Wolfe, Victoria Mar","doi":"10.15430/JCP.25.007","DOIUrl":"10.15430/JCP.25.007","url":null,"abstract":"<p><p>Keratinocyte cancer burden is escalating, particularly in older Australian adults, where the incidence was > 6,000/100,000 in persons aged 80 to 84 per year, compared with 26/100,000 in persons aged 20 to 24 per year, in Queensland between 2011 to 2014. Keratinocyte cancers are estimated to account for 25% of all cancer-related hospitalisations and > $1 billion in treatment costs per year in Australlia. This undoubtedly leads to a large strain on the medical system, as well as amplifying patient morbidity and mortality. Those who are immunosuppressed, or with haematological malignancy or a solid organ transplant, are typically at highest risk of developing a keratinocyte cancer; however, older adults, and especially UV exposed Caucasian populations are increasingly requiring treatment for several keratinocyte cancers every year. This has resulted in an acute, urgent need for efficacious, tolerable, safe chemoprevention agents that could decrease keratinocyte cancer burden. Aspirin has been investigated as a chemopreventive agent for many years in other cancers. In this narrative review, the role for aspirin in the chemoprevention of keratinocyte cancers is discussed.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"30 2","pages":"59-74"},"PeriodicalIF":2.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}